Mia Sandberg Lundblad

LU Holding AB (LU Holding) is a venture capital subsidiary of University of Lund founded in 1994. The firm is headquartered in Lund, Sweden.

Saga Diagnostics AB operates as a personalized cancer medicine and disease monitoring company. The firm's services include Gene Mutation analysis, circulating tumor DNA and Chromosome analysis. The company was founded by Lao Saal and Anthony George in 2016 and is headquartered in Lund, Sweden.

Akuru Pharma AB engages in the development of research and technology. It focuses on exploiting the abnormal expression of transporter proteins in kidney cancer for developing novel diagnostic and treatment modalities. The company was founded by Jennifer Hansson, Hakan Axelson, and Johanna Asklin on April 14, 2016 and is headquareterd in Lund, Sweden.

SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden.

Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden.